MEDIFAST INC Common Stock (MED)

FairStock Score: 39/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Medifast traded at $11.67, a market value of $130.5M. FairStock's calculations show a P/B of 0.61, a negative P/E of -5.01, ROE of -12.42%, ROCE of -4.60%, debt-to-equity of 0.14, and trailing free cash flow of $4.0M for a 3.1% FCF yield. The filed figures tell a difficult story. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $76.4M and net income was -$3.1M, or EPS -$0.28. A year earlier, in fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $105.6M, net income $2.5M, and EPS $0.22. For FY2025, the year ended 2025-12-31, revenue was $385.8M and net income -$18.7M, versus FY2024, the year ended 2024-12-31, revenue $602.5M and net income $2.1M. FY2023, the year ended 2023-12-31, was much stronger: revenue $1.1B and net income $99.4M. This is a contraction, not a compounder. FairStock calls it a TURNAROUND because of a loss in the latest year after earlier profits. The low debt and positive trailing free cash flow give it some time, and the Altman Z-Score of 3.02 does not signal immediate balance-sheet distress. But a Piotroski F-Score of 4/9 and negative returns on capital show fragility. The stock looks statistically cheap against book value, yet cheapness without stabilizing revenue and positive earnings is not a margin of safety. I would want proof the business has stopped shrinking.

In plain English: Medifast sells weight-loss and healthy-living products, often with coaching. Revenue has fallen sharply and the company is losing money now, though it has little debt and still brings in some cash. The stock price looks low compared with its accounting value, but the business is weak, so it is not a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer